Skip to content
Peptigraph home

AOD-9604

HGH fragment analog. AOD-9604 is not FDA approved for any use.

Also called:AOD
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Animal evidence, 2 of 4
StatusNot FDA approved · research chemicalProhibited by WADA (S2.2.3)Full legal history

Key facts

Class
HGH fragment analog
Also called
AOD
Vial sizes sold
2 mg, 5 mg, 10 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
Not approved
research chemical
WADA
Prohibited (S2.2.3)
In and out of competition
Everything on AOD-9604

AOD-9604 guides

Vial and dose sizes

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

AOD-9604: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger3Animal evidence, 2 of 4International journal of obesity and related metabolic disorders 2001, PMID 11673763

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A fragment of growth hormone, not growth hormone

AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone; the cited rat study examined its metabolic actions in obese Zucker rats.[8]

In obese mice, unlike hGH, it did not induce hyperglycaemia or reduce insulin secretion. This is mouse data.[4]

What the cached evidence covers

The headline animal result: daily oral dosing in obese Zucker rats reduced body weight gain by over 50% (15.8 vs 35.6 g) versus controls.[8]

The mouse work also shows a limit: in mice lacking the beta-3 adrenergic receptor, the effect on weight and lipolysis did not appear.[9]

The only human trial mention is a drug profile saying that phase IIa trials were underway; no human trial results are in the cached literature.[10]

A rabbit study of injections into an arthritic knee reported enhanced cartilage regeneration; this is an animal result.[5]

Regulatory path

FDA lists no approved AOD-9604 product.[2]

FDA's safety-risk table says compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes of administration.[3]

WADA's list names AOD-9604 among growth hormone fragments.[1]

Compared with

Common stacks

AOD-9604 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is AOD-9604 FDA approved?

No. AOD-9604 is not FDA approved for any use.

Is AOD-9604 banned in sport?

Yes. Prohibited by WADA (S2.2.3), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What does AOD-9604 do?

In obese rats it cut weight gain over 50% versus controls; human results are not in the cached literature.[8]

Is AOD-9604 a peptide?

Yes, a synthetic fragment based on the lipolytic region of hGH.[8]

Is there oral AOD-9604?

The rat study used an oral dose, so oral delivery has been tried in animals; human oral data were not found.[8]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "aod-9604" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: AOD-9604 appears in FDA's table of bulk drug substances previously in category 2 and withdrawn by the nominators.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
  5. 5Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  6. 6PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  8. 8Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  9. 9The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
  10. 10AOD-9604 Metabolic.Current opinion in investigational drugs (London, England : 2000) · 2004PMID 15134286Accessed 2 Oct 2026

Found an error? Report a correction.